Report the final analysis of the Phase 3 fianlimab and Libtayo melanoma study
Delivered after the deadline (211 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 May 2024
- Due
- 31 Dec 2025
- Delivered
- 30 Jul 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“This study is enrolling faster than expected and will be conducted solely as a Phase 3 study with the final analysis to be reported during 2025.”
What we found
Evidence strength A What the grades mean
Filings after the 2025 deadline moved the first-line metastatic melanoma Phase 3 readout to 1H and then Q2 2026. The 10-Q filed 2026-07-30 reports results, which did not reach statistical significance.
-
A Regeneron Pharmaceuticals 10-K filed 2026-02-04
“Report results from Phase 3 study versus pembrolizumab in first-line metastatic melanoma (first half 2026)” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2026-04-29
“Report results from Phase 3 study in combination with Libtayo versus pembrolizumab in first-line metastatic melanoma (second quarter 2026)” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2026-07-30
“Reported that Phase 3 study versus pembrolizumab in first-line metastatic melanoma did not reach statistical significance for primary endpoint” ✓ confirmed on the page
Market reaction: the shares moved +3.3% against the S&P 500 over the three sessions around the disclosure (3 Feb 2026 to 6 Feb 2026). What this measures
Checked 11 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Report
- Deliverable
- Final analysis of Phase 3 fianlimab plus Libtayo melanoma study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-REGN-006348 · Corrections policy